Please use this identifier to cite or link to this item:
DC FieldValue
dc.titleOutcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics
dc.contributor.authorDan, Y.-Y.
dc.contributor.authorWai, C.-T.
dc.contributor.authorLee, Y.-M.
dc.contributor.authorSutedja, D.S.
dc.contributor.authorSeet, B.-L.
dc.contributor.authorLim, S.-G.
dc.identifier.citationDan, Y.-Y., Wai, C.-T., Lee, Y.-M., Sutedja, D.S., Seet, B.-L., Lim, S.-G. (2005-07-28). Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World Journal of Gastroenterology 11 (28) : 4344-4350. ScholarBank@NUS Repository.
dc.description.abstractAim: We set to determine factors that determine clinical severity after the development of resistance. Methods: Thirty-five Asian patients with genotypic lamivudine resistance were analyzed in three groups: 13/35 (37%) were non-cirrhotics with normal pre-treatment ALT (Group IA), 12/35 (34%) were non-cirrhotics with elevated pre-treatment ALT (Group IB), and 10/35 (29%) were cirrhotics (Group II). Patients were followed for a median of 98 wk (range 26-220) after the emergence of genotypic resistance. Results: Group IA patients tended to retain normal ALT. Group IB patients showed initial improvement of ALT with lamivudine but 9/12 patients (75%) developed abnormal ALT subsequently. On follow-up however, this persisted in only 33%. Group II patients also showed improvement while on treatment, but they deteriorated with the emergence of resistance with 30% death from decompensated liver disease. Pretreatment ALT levels and CPT score (in the cirrhotic group) were predictive of clinical resistance and correlated with peak ALT levels and CPT score. Conclusion: The phenotype of lamivudine-resistant HBV correlated with the pretreatment phenotype. The clinical course was generally benign in non-cirrhotics. However, cirrhotics had a high risk of progression and death (30%) with the development of lamivudine resistance. © 2005 The WJG Press and Elsevier Inc. All rights reserved.
dc.subjectHepatitis B treatment
dc.subjectLamivudine resistance
dc.subjectNucleoside analog
dc.subjectYMDD mutants
dc.description.sourcetitleWorld Journal of Gastroenterology
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Page view(s)

checked on Feb 2, 2023

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.